SCHEMBL6330955

SCHEMBL6330955

COC(=O)CCCCOc1ccc(F)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
LTA4H P09960 3/20 0.52
FAAH O00519 2/20 0.51
ALDH1A1 P00352 3/20 0.49
USP2 O75604 1/20 0.49
HPGD P15428 1/20 0.49
LMNA P02545 1/20 0.49
MAPT P10636 1/20 0.49
HTT P42858 1/20 0.49
KMT2A Q03164 1/20 0.49
HSD17B10 Q99714 1/20 0.49
PDE3B Q13370 1/20 0.48
PDE3A Q14432 1/20 0.48
P2RY12 Q9H244 1/20 0.48
HDAC3 O15379 3/20 0.48
HDAC4 P56524 3/20 0.48
HDAC1 Q13547 3/20 0.48
HDAC7 Q8WUI4 3/20 0.48
HDAC2 Q92769 3/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6329715 0.95 LTA4H (0.54) KDM4ESMN1; SMN2LTA4HFAAHALDH1A1
SCHEMBL21991820 0.90 LTA4H (0.55) KDM4ESMN1; SMN2LTA4HFAAHALDH1A1
SCHEMBL4275826 0.90 HDAC1 (0.56) LTA4HALDH1A1LMNAMAPTHTT
SCHEMBL9034669 0.85 L3MBTL1 (0.59) LTA4HALDH1A1HPGDLMNAMAPT
SCHEMBL14566050 0.85 MAPT (0.56) SMN1; SMN2ALDH1A1HPGDLMNAMAPT
SCHEMBL5493279 0.84 LTA4H (0.53) KDM4ESMN1; SMN2LTA4HFAAHMAPT
SCHEMBL809948 0.83 NR5A1 (0.59) LTA4HALDH1A1LMNAMAPTHTT
SCHEMBL810018 0.83 PPARD (0.53) LTA4HALDH1A1LMNAMAPTHTT
SCHEMBL21260769 0.83 L3MBTL1 (0.57) ALDH1A1HPGDLMNAMAPTHTT
SCHEMBL14163893 0.83 L3MBTL1 (0.57) ALDH1A1HPGDLMNAMAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6867023-B2 Production method of polyhydroxyalkanoate from substituted fatty acid ester as raw material CANON KABUSHIKI KAISHA (JP) 2005-03-15 US claimed
US-20020081646-A1 Production method of polyhydroxyalkanoate form substituted fatty acid ester as raw material CANON KABUSHIKI KAISHA (JP) 2002-06-27 US claimed
EP-1201763-A2 Production method of polyhydroxyalkanoate from substituted fatty acid ester as raw material CANON KABUSHIKI KAISHA (JP) 2002-05-02 EP claimed
US-6867023-B2 Production method of polyhydroxyalkanoate from substituted fatty acid ester as raw material CANON KABUSHIKI KAISHA (JP) 2005-03-15 US disclosed
US-20020081646-A1 Production method of polyhydroxyalkanoate form substituted fatty acid ester as raw material CANON KABUSHIKI KAISHA (JP) 2002-06-27 US disclosed
EP-1201763-A2 Production method of polyhydroxyalkanoate from substituted fatty acid ester as raw material CANON KABUSHIKI KAISHA (JP) 2002-05-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020081646-A1 Production method of polyhydroxyalkanoate form substituted fatty acid ester as raw material FASN, FFAR1, ACADM KDM4E 1818/4885SMN1; SMN2 4772/4885LTA4H 210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.